PRLDPrelude Therapeutics Incorporated
$3.88+169% 1Y
$3.88
$1.1952 weeks$6.62
The financials
Prelude Therapeutics Incorporated by the numbers
Prelude Therapeutics Incorporated (PRLD) reported revenue of $5.7M in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $14M. For the full year FY2025, revenue was $12M (+73% year on year) and net income −$99M. The next results filing is expected around Nov 11, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $5.7M | $0 | n/a |
| Operating income | −$15M | −$32M | n/a |
| Net income | −$14M | −$31M | n/a |
| Diluted EPS | −$0.14 | −$0.41 | n/a |